Vizgen

Vizgen

Biotechnology for spatial genomics research

About Vizgen

Simplify's Rating
Why Vizgen is rated
A
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A+ on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

51-200

Company Stage

Series C

Total Funding

$136.2M

Headquarters

Cambridge, Massachusetts

Founded

2019

Overview

Vizgen specializes in spatial genomics, focusing on high-resolution imaging to analyze biological samples at the cellular level. Its main product, MERSCOPE, utilizes MERFISH chemistry to collect detailed spatial data, which is especially beneficial for research in immuno-oncology, helping scientists understand tumor and immune interactions in various cancers. The MERSCOPE platform is complemented by a Gene Panel Design Portal, allowing researchers to create custom gene panels, and a cell segmentation tool called VPT, which accurately defines cell boundaries using MERFISH data. Unlike competitors, Vizgen's integrated approach combines advanced imaging with user-friendly tools for gene panel design and cell analysis. The company's goal is to enhance research capabilities in genomics and cancer biology by providing comprehensive tools and services to research institutions and laboratories.

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for spatial transcriptomics in drug discovery boosts Vizgen's market potential.
  • Partnerships with companies like Scale Biosciences enhance research capabilities and product offerings.
  • Recent capital raise supports Vizgen's long-term growth and technology development.

What critics are saying

  • Ongoing legal battles with 10x Genomics and Harvard could drain resources and distract operations.
  • Emerging competition from Scale Biosciences may lead to market share erosion.
  • Operational streamlining and headcount reduction may impact employee morale and efficiency.

What makes Vizgen unique

  • Vizgen's MERFISH technology offers high accuracy and detection efficiency at subcellular resolution.
  • MERSCOPE platform integrates single-cell and spatial multiomics analyses for detailed tissue understanding.
  • Gene Panel Design Portal and VPT tool enhance user experience and research capabilities.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$136.2M

Above

Industry Average

Funded Over

3 Rounds

Series C funding is usually for startups that are doing well and are looking for more money to fuel major growth, such as acquiring other companies, expanding into global markets, or launching new product lines. Investors typically include larger venture capital firms and private equity.
Series C Funding Comparison
Above Average

Industry standards

$50M
$50M
Medium
$62M
SeatGeek
$85.2M
Vizgen
$100M
Oura

Growth & Insights and Company News

Headcount

6 month growth

-6%

1 year growth

-3%

2 year growth

8%
BioSpace
Apr 3rd, 2025
Vizgen Announces End of Litigation with 10x Genomics and Harvard University

Vizgen announces end of litigation with 10x Genomics and Harvard University.

Business Wire
Mar 25th, 2025
Vizgen Announces New Appointments to Board of Directors and Executive Leadership Team

Christian Uhrich, Investment Director at M Ventures, joins Vizgen Board of Directors; Chad Brown joins the company as Chief Commercial Officer

BioSpace
Dec 18th, 2024
Vizgen Launches Certified Service Provider (CSP) Program, Expanding Access to Single-Cell Spatial Genomics Technology

Vizgen launches Certified Service Provider (CSP) Program, expanding access to single-cell spatial genomics technology.

Business Wire
May 7th, 2024
Vizgen Announces Significant Win In Ongoing Patent Litigation Against 10X Genomics And Harvard University

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has achieved a significant victory in its ongoing legal battle with 10x Genomics and Harvard University. The U.S. District Court recently ruled in Vizgen’s favor, allowing Vizgen to expand its case based on new evidence uncovered during discovery in the litigation. The Court’s ruling substantially strengthens Vizgen’s position against 10x Genomics and Harvard, who must now defend against additional allegations of antitrust violations. Despite strenuous objections from 10x and Harvard, the Court approved Vizgen’s request to amend the claims to include additional antitrust allegations relating to 10x’s anticompetitive economic practices. These new allegations bolster Vizgen’s existing antitrust counterclaims against both 10x and Harvard, accusing them of conspiring to monopolize the market and obstructing Vizgen’s ability to compete globally

Business Wire
Apr 16th, 2024
Vizgen Issued A New Us Patent For Its Merfish Technology

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, announced today the issuance by the US Patent Office of a patent that covers the in situ imaging of the spatial transcriptome. U.S. Patent No. 11,959,075 is for robust multiplex imaging of RNA and its spatial organization in a sample. "This latest patent relates to our MERFISH technology and enables groundbreaking advancements in the spatial genomics landscape," said Terry Lo, CEO, Vizgen, Inc. "It is another patent underscoring Vizgen’s leadership in the field, providing the industry’s best tools for single-cell spatial biology, and driving discoveries aimed at improving human health," he said

There are no jobs for Vizgen right now.

Find jobs on Simplify and start your career today

💡
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →